Work

Therapeutic Approaches to RAS Mutation

Year: 2016

Type: review

Abstract: The study of oncogenic RAS mutations has led to crucial discoveries regarding cancer molecular biology and behavior and has been integral in shaping the era of targeted cancer therapy. RAS mutations are one of the most common oncogenic drivers in human cancer, and intense efforts to find a clinically effective inhibitor are ongoing. Despite these efforts, targeting RAS mutations has remained elusive, so much so that some have termed oncogenic RAS mutations as "undruggable." In this review, we will summarize current understanding of RAS biology, explore strategies to inhibit RAS oncoproteins and its downstream effectors, and discuss recently described complexities that have shed new light on this pursuit.

Source: The Cancer Journal

DOI: 10.1097/ppo.0000000000000187

Authors: Aaron J. Scott, Christopher H. Lieu, Wells A. Messersmith

Institutions: University of Colorado Cancer Center, University of Colorado Anschutz, University of Colorado Denver

Language: French

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute